国旅文化投资集团股份有限公司发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（上会稿）深度解读
一、交易概况与核心要点
国旅文化投资集团股份有限公司（证券代码：600358，简称“国旅联合”）拟通过发行股份及支付现金方式购买江西润田实业股份有限公司（以下简称“润田实业”）100%股权，并同步募集配套资金。此次交易总价高达30.09亿元人民币，标的资产为包装饮用水行业的龙头企业“润田实业”，该公司主营纯净水和矿泉水，是中国饮料行业包装饮用水及天然矿泉水全国“双十强”，拥有“中国驰名商标”“江西省著名商标”等品牌资源，盈利能力突出，2023年净利润为1.45亿元，2024年净利润为1.76亿元，未来三年业绩承诺净利润分别不低于1.8253亿元、1.9430亿元、2.0657亿元。
本次交易涉及三方股东：江西迈通健康饮品开发有限公司（持股51%）、江西润田投资管理有限公司（持股24.7%）、南昌金开资本管理有限公司（持股24.3%）。支付方式为现金及股份，现金对价共计90270万元，股份对价210630万元。股份发行价格为3.20元/股，发行数量为658,218,749股，发行后总股本将达1,163,155,409股。
二、募集配套资金安排
配套募集资金最高不超过9.3亿元，发行对象为不超过35名特定投资者，资金主要用于支付现金对价以及中介机构费用。募集资金股票自发行结束之日起6个月内不得转让。
三、影响与价格敏感信息
- 盈利与资产规模大幅提升：重组后公司总资产、净资产、营业收入、净利润等各项指标将显著增长。2025年10月末备考数据显示，总资产将增至21.76亿元（同比增长379%），归属于母公司股东的所有者权益增至15.30亿元（增长2881%），营业收入增至16.15亿元（增长350%），净利润增至1.84亿元（扭亏为盈）。资产负债率大幅下降至29.41%，增强公司抗风险能力。
- 股权结构变化：江西迈通将成为控股股东（持股28.86%），江西省国资委通过江西迈通、江旅集团及南昌江旅合计控制上市公司39.41%股份，实际控制人不变。
- 业绩承诺与补偿安排：若润田实业未达业绩承诺，交易对方需以股份或现金方式进行补偿，补偿总额不超过交易价格。业绩承诺期为交易完成后连续三年，减值测试补偿机制进一步保障投资者利益。
- 股份锁定与减持承诺：交易对方及上层股东出具穿透锁定承诺，最长锁定期达36个月，上市公司控股股东及高管无减持计划。若违反承诺，减持所得归上市公司所有，并承担赔偿责任。
- 即期回报摊薄风险：重组后每股收益提升，但若未来业务增长不及预期，存在每股收益指标下降风险。公司拟完善治理结构、分配政策，采取填补回报措施保障中小股东权益。
- 免于要约收购：江西迈通、江旅集团及南昌江旅合计持股比例将超过30%，已获股东大会豁免要约收购义务，股份三年内不得转让。
- 重大风险提示：交易需获得上交所审核及中国证监会注册，存在审批风险。募集配套资金能否足额到位存不确定性。标的资产评估增值率高达153.83%，存在未来实际情况与评估假设不一致风险。标的公司业务整合、业绩达成、商誉减值、亏损弥补、市场竞争、销售区域集中、新产品开拓、水源地风险等均需投资者重点关注。
- 重要承诺：交易各方、上市公司及高管均出具关于信息真实性、避免同业竞争、规范关联交易、保证公司独立性、股份锁定、无减持、填补回报等承诺，保障投资者合法权益。
四、交易必要性与协同效应
本次交易响应国家政策，落实国企改革要求，完善公司消费产业链布局。润田实业注入上市公司，有利于提升品牌价值、实现资源资产化、资产证券化。上市公司与润田实业将在品牌推广、渠道协同、客户资源及新产品开发等方面形成协同效应，助力双方高质量发展。
五、对投资者的建议
本次重大资产重组将极大改善上市公司盈利能力和资产质量，是公司战略升级和产业整合的重要举措。投资者应重点关注交易审批进度、配套资金到位、业绩承诺达成、商誉减值、市场竞争等风险，结合自身风险偏好审慎决策。
免责声明
本新闻稿仅供投资者参考，不构成投资建议。投资者需结合自身风险承受能力，关注公司后续公告及相关风险提示。公司及相关中介机构承诺信息披露真实、准确、完整，如后续出现重大变化，公司将及时公告。
English Version:
Guolv Cultural Investment Group Co., Ltd. Share Issuance, Cash Payment for Asset Acquisition, and Supporting Fundraising (Draft for Review) – Investor Deep Dive
1. Transaction Overview & Key Highlights
Guolv Cultural Investment Group Co., Ltd. (stock code: 600358, “Guolv United”) plans to acquire 100% equity in Jiangxi Runtian Industrial Co., Ltd. (“Runtian Industrial”) by issuing shares and paying cash, simultaneously raising supporting funds. The total transaction value is RMB 3.009 billion. Runtian Industrial is a leading player in the bottled water industry, ranked as a “Top Ten” in both bottled water and natural mineral water nationwide, with renowned brands and strong profitability, posting net profits of RMB 145 million in 2023 and RMB 176 million in 2024. The three-year performance commitment stands at no less than RMB 182.53 million, RMB 194.30 million, and RMB 206.57 million in net profit, respectively.
The transaction involves three shareholders: Jiangxi Maitong Health Beverage Development Co., Ltd. (51%), Jiangxi Runtian Investment Management Co., Ltd. (24.7%), and Nanchang Jinkai Capital Management Co., Ltd. (24.3%). Payment combines cash and shares; cash consideration totals RMB 902.7 million, share consideration RMB 2.1063 billion. The issue price is RMB 3.20/share, with 658,218,749 shares to be issued, resulting in a new total share capital of 1,163,155,409 shares post-transaction.
2. Supporting Fundraising Arrangement
Supporting funds of up to RMB 930 million will be raised from no more than 35 specific investors, mainly to cover the cash consideration and intermediary fees. Shares issued in this process will be locked for six months after issuance.
3. Impact & Price-sensitive Information
- Major Growth in Profit & Asset Scale: Post-restructuring, total assets, net assets, revenue, and net profit will all surge. 2025 October pro forma figures show assets at RMB 2.176 billion (up 379%), equity at RMB 1.53 billion (up 2881%), revenue at RMB 1.614 billion (up 350%), net profit at RMB 184 million (turning profitable). Asset-liability ratio drops sharply to 29.41%, boosting risk resilience.
- Shareholding Structure Shift: Jiangxi Maitong becomes controlling shareholder (28.86%), while Jiangxi SASAC via Maitong, Jianglv Group & Nanchang Jianglv controls 39.41%. Actual controller unchanged.
- Performance Commitment & Compensation: If Runtian fails to meet commitments, counterparties must compensate with shares or cash, capped at the deal value. Three-year commitment, impairment test for additional protection.
- Share Lock-up & Sell-down Commitments: Counterparties and upper-level shareholders provide lock-up pledges, max 36 months. Controlling shareholders and executives have no sell-down plans; violations mean proceeds go to the company and compensation applies.
- Dilution Risk: EPS will rise post-deal, but future underperformance may see EPS decline. Company will improve governance and payout policies, with measures to protect minority shareholders.
- Waiver of Mandatory Offer: Combined shareholding exceeds 30%; EGM has waived mandatory offer obligations, shares locked for three years.
- Major Risk Warnings: Approval from SSE and CSRC needed, with uncertainties. Fundraising sufficiency is uncertain. Asset value assessment shows 153.83% premium, risk of actual outcomes diverging from assumptions. Integration, performance, goodwill impairment, loss recovery, competition, sales concentration, product innovation, water source risks all highlighted for investors.
- Key Commitments: All parties and company executives pledge information authenticity, avoidance of competition, regulated related-party transactions, company independence, share lock-up, no sell-down, and return enhancement measures, safeguarding investor rights.
4. Transaction Necessity & Synergies
The deal responds to national policy, implements SOE reform, and enhances consumer industry chain layout. Injecting Runtian Industrial into the listed company boosts brand value, achieves resource assetization and securitization. Synergies include brand promotion, channel coordination, customer resource integration, and new product development.
5. Investor Advice
This major asset restructuring will substantially improve profitability and asset quality, marking a strategic upgrade and industry integration. Investors should monitor deal approval progress, fundraising, performance completion, goodwill impairment, and competitive risks, and act prudently in line with risk tolerance.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should assess their own risk tolerance and monitor subsequent company disclosures and risk warnings. The company and intermediaries promise truthful, accurate, and complete information; any major changes will be disclosed in a timely manner.
